Qiagen N.V. (QGEN): Cash & Equivalents
$839.00M
As of 2025-12-31
+4.7%
3-year compound annual growth
+7.0%
5-year compound annual growth
+11.2%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $839.00M | +26.4% | 2026-03-20, Balance as of period end |
| 2024-12-31 | $663.55M | -0.7% | 2026-03-20, Balance as of period end |
| 2023-12-31 | $668.08M | -8.6% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $730.67M | -17.0% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $880.52M | +47.2% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $597.98M | -4.1% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $623.65M | -46.2% | 2021-03-05, Balance as of period end |
| 2018-12-31 | $1.16B | +76.2% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $657.71M | +49.8% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $439.18M | +51.4% | 2019-03-06, Balance as of period end |
| 2015-12-31 | $290.01M | -26.1% | 2018-03-06, Balance as of period end |
| 2014-12-31 | $392.67M | +18.9% | 2017-03-06, Balance as of period end |
| 2013-12-31 | $330.30M | -16.2% | 2016-02-29, Balance as of period end |
| 2012-12-31 | $394.04M | +78.2% | 2015-03-02, Balance as of period end |
| 2011-12-31 | $221.13M | -73.3% | 2014-03-03, Balance as of period end |
| 2010-12-31 | $828.41M | +0.3% | 2013-03-04, Balance as of period end |
| 2009-12-31 | $825.56M | +147.7% | 2012-03-27, Balance as of period end |
| 2008-12-31 | $333.31M | n/a | 2011-03-21, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Qiagen N.V. (QGEN) | 2025-12-31 | $839.00M | +26.4% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $2.60B | +34.7% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $133.82M | +15.5% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Novavax Inc (NVAX) | 2025-12-31 | $240.63M | -54.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
Compare QGEN, MRNA, EXEL, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗